Targeting Macrophage-to-Myofibroblast Transition Mitigates Progression from Inflammation to Fibrosis in Rosacea

Chengqian Chen1, Peiru Wang1, Yajing Cao1

  • 1Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200092, China.

Insights

This study reveals macrophage-to-myofibroblast transition (MMT) drives fibrotic remodeling in rosacea. Bruceine A (BA) targets STAT3 palmitoylation, reducing MMT and inflammation for potential rosacea treatment.

Area of Science:

  • Dermatology
  • Immunology
  • Molecular Biology

Background:

  • Rosacea is a chronic inflammatory skin disease with limited treatments.
  • Macrophage infiltration is a key feature, but their role in fibrosis is unclear.
  • Fibrotic remodeling contributes to rosacea pathology and reduced quality of life.

Purpose of the Study:

  • To investigate the role of macrophages in rosacea-associated fibrotic remodeling.
  • To identify molecular mechanisms driving fibrosis in rosacea.
  • To discover novel therapeutic targets and agents for rosacea.

Main Methods:

  • Serum proteomics and single-cell RNA sequencing (scRNA-seq) on human rosacea biopsies.
  • Spatial transcriptomics (ST) and histological analysis of skin samples.
  • LL37-induced mouse models with macrophage depletion and lineage tracing.

Main Results:

  • Macrophages transition to myofibroblasts (MMT), driving fibrotic remodeling in rosacea.
  • Elevated TGF-β1 and STAT3 signaling were observed in patient samples.
  • Macrophage depletion and Bruceine A (BA) treatment reduced fibrosis and inflammation in mouse models.
  • BA inhibits STAT3 palmitoylation, disrupting pro-fibrotic and inflammatory pathways.

Conclusions:

  • Macrophage-to-myofibroblast transition (MMT) is a key driver of fibrotic remodeling in rosacea.
  • STAT3 palmitoylation represents a novel therapeutic target for rosacea.
  • Bruceine A (BA) demonstrates dual-action potential for treating rosacea by targeting MMT and inflammation.